Preoperative Patient Education and Smaller Prescription Quantity Reduce Opioid Use After Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis: Results of a Prospective Study
Background: Most opioids prescribed postoperatively are unused. Leftover opioids are a major source of nonmedical opioid use among adolescents. Postoperative opioid use has also been associated with prescription quantity. Our purpose was to evaluate the effect of preoperative patient education and implementation of evidence-based prescribing guidelines on opioid use and pain level after posterior spinal fusion (PSF) for adolescent idiopathic scoliosis (AIS). Methods: AIS patients aged 10 to 17 years undergoing PSF were prospectively enrolled [postintervention cohort (POST-INT)]. Previous data on 77 patients show...
Source: Journal of Pediatric Orthopaedics - August 11, 2022 Category: Orthopaedics Tags: Scoliosis Source Type: research

A peripheral opioid antagonist for treating urinary retention induced by opioids: A case report
Palliat Med. 2022 Aug 8:2692163221107109. doi: 10.1177/02692163221107109. Online ahead of print.ABSTRACTBACKGROUND: Urinary retention is a poorly studied opioid-related adverse effect. There is a paucity of data regarding the treatment of such disturbance in patients with advanced cancer receiving opioids.ACTUAL CASE: A young man, without comorbidities, was receiving 30 mg/day of oxycodone for abdominal pain due to pancreatic cancer, unsuccessfully. He also complained of severe urinary retention that developed after initiation of opioid therapy. Methadone therapy was effective on pain intensity, but bladder dysfunction per...
Source: Palliative Medicine - August 9, 2022 Category: Palliative Care Authors: Sebastiano Mercadante Source Type: research

A peripheral opioid antagonist for treating urinary retention induced by opioids: A case report
Palliat Med. 2022 Aug 8:2692163221107109. doi: 10.1177/02692163221107109. Online ahead of print.ABSTRACTBACKGROUND: Urinary retention is a poorly studied opioid-related adverse effect. There is a paucity of data regarding the treatment of such disturbance in patients with advanced cancer receiving opioids.ACTUAL CASE: A young man, without comorbidities, was receiving 30 mg/day of oxycodone for abdominal pain due to pancreatic cancer, unsuccessfully. He also complained of severe urinary retention that developed after initiation of opioid therapy. Methadone therapy was effective on pain intensity, but bladder dysfunction per...
Source: Palliative Medicine - August 9, 2022 Category: Palliative Care Authors: Sebastiano Mercadante Source Type: research

On what basis did Health Canada approve OxyContin in 1996?: A retrospective analysis of regulatory data
Clin Trials. 2022 Aug 4:17407745221108436. doi: 10.1177/17407745221108436. Online ahead of print.ABSTRACTThe marketing and sale of oxycodone (OxyContin) by Purdue Pharma has commanded a great deal of legal and policy attention due to the drug's central role in the ongoing overdose crisis. However, little is known about the basis for OxyContin's approval by regulators, such as Health Canada in 1996. Taking advantage of a recently created online database containing information pertaining to the safety and effectiveness of drugs, we conducted a retrospective analysis of Purdue Pharma's submission to Health Canada, including b...
Source: Clinical Trials - August 4, 2022 Category: Research Authors: Jessie Pappin Itai Bavli Matthew Herder Source Type: research

On what basis did Health Canada approve OxyContin in 1996?: A retrospective analysis of regulatory data
Clin Trials. 2022 Aug 4:17407745221108436. doi: 10.1177/17407745221108436. Online ahead of print.ABSTRACTThe marketing and sale of oxycodone (OxyContin) by Purdue Pharma has commanded a great deal of legal and policy attention due to the drug's central role in the ongoing overdose crisis. However, little is known about the basis for OxyContin's approval by regulators, such as Health Canada in 1996. Taking advantage of a recently created online database containing information pertaining to the safety and effectiveness of drugs, we conducted a retrospective analysis of Purdue Pharma's submission to Health Canada, including b...
Source: Clinical Trials - August 4, 2022 Category: Research Authors: Jessie Pappin Itai Bavli Matthew Herder Source Type: research

On what basis did Health Canada approve OxyContin in 1996?: A retrospective analysis of regulatory data
Clin Trials. 2022 Aug 4:17407745221108436. doi: 10.1177/17407745221108436. Online ahead of print.ABSTRACTThe marketing and sale of oxycodone (OxyContin) by Purdue Pharma has commanded a great deal of legal and policy attention due to the drug's central role in the ongoing overdose crisis. However, little is known about the basis for OxyContin's approval by regulators, such as Health Canada in 1996. Taking advantage of a recently created online database containing information pertaining to the safety and effectiveness of drugs, we conducted a retrospective analysis of Purdue Pharma's submission to Health Canada, including b...
Source: Clinical Trials - August 4, 2022 Category: Research Authors: Jessie Pappin Itai Bavli Matthew Herder Source Type: research

On what basis did Health Canada approve OxyContin in 1996?: A retrospective analysis of regulatory data
Clin Trials. 2022 Aug 4:17407745221108436. doi: 10.1177/17407745221108436. Online ahead of print.ABSTRACTThe marketing and sale of oxycodone (OxyContin) by Purdue Pharma has commanded a great deal of legal and policy attention due to the drug's central role in the ongoing overdose crisis. However, little is known about the basis for OxyContin's approval by regulators, such as Health Canada in 1996. Taking advantage of a recently created online database containing information pertaining to the safety and effectiveness of drugs, we conducted a retrospective analysis of Purdue Pharma's submission to Health Canada, including b...
Source: Clinical Trials - August 4, 2022 Category: Research Authors: Jessie Pappin Itai Bavli Matthew Herder Source Type: research

On what basis did Health Canada approve OxyContin in 1996?: A retrospective analysis of regulatory data
Clin Trials. 2022 Aug 4:17407745221108436. doi: 10.1177/17407745221108436. Online ahead of print.ABSTRACTThe marketing and sale of oxycodone (OxyContin) by Purdue Pharma has commanded a great deal of legal and policy attention due to the drug's central role in the ongoing overdose crisis. However, little is known about the basis for OxyContin's approval by regulators, such as Health Canada in 1996. Taking advantage of a recently created online database containing information pertaining to the safety and effectiveness of drugs, we conducted a retrospective analysis of Purdue Pharma's submission to Health Canada, including b...
Source: Clinical Trials - August 4, 2022 Category: Research Authors: Jessie Pappin Itai Bavli Matthew Herder Source Type: research

On what basis did Health Canada approve OxyContin in 1996?: A retrospective analysis of regulatory data
Clin Trials. 2022 Aug 4:17407745221108436. doi: 10.1177/17407745221108436. Online ahead of print.ABSTRACTThe marketing and sale of oxycodone (OxyContin) by Purdue Pharma has commanded a great deal of legal and policy attention due to the drug's central role in the ongoing overdose crisis. However, little is known about the basis for OxyContin's approval by regulators, such as Health Canada in 1996. Taking advantage of a recently created online database containing information pertaining to the safety and effectiveness of drugs, we conducted a retrospective analysis of Purdue Pharma's submission to Health Canada, including b...
Source: Clinical Trials - August 4, 2022 Category: Research Authors: Jessie Pappin Itai Bavli Matthew Herder Source Type: research

Correction to: Impact of Policy Interventions on Oxycodone Prescribing in Queensland, Australia: An Uncontrolled Interrupted Time Series Study
(Source: Drug Safety)
Source: Drug Safety - August 4, 2022 Category: Drugs & Pharmacology Source Type: research

Shared decision-making for postoperative opioid prescribing and preoperative pain management education decreases excess opioid burden
ConclusionInstitution of procedure-specific prescribing recommendations and preoperative pain management education using shared decision-making between patient and provider decreases opioid excess burden, resulting in fewer unused narcotic pills entering the community. Furthermore, allowing patients to participate in decision-making with their provider results in increased patient satisfaction.Graphical abstract (Source: Surgical Endoscopy)
Source: Surgical Endoscopy - August 2, 2022 Category: Surgery Source Type: research

Shared Decision-Making Tool for Opioid Prescribing After Ambulatory Orthopedic Surgery in Veterans: A Randomized Controlled Clinical Trial
CONCLUSIONS: The shared-tool group had equivalent or better pain control and were prescribed a lower number of opioid pain pills than the no-tool group. Both groups used nonopioid medications, with no difference in the types of over-the-counter medications used. Shared decision-making strategies could be applied to other outpatient orthopedic surgical settings, and may reduce the amount of opioids prescribed without compromising pain control.TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic II.PMID:35880150 | PMC:PMC9308163 | DOI:10.1016/j.jhsg.2022.05.003 (Source: Hand Surgery)
Source: Hand Surgery - July 26, 2022 Category: Surgery Authors: Rajshri Bolson Andy Lalka Hannah Korrell Sarah E Sibbel Karsten Bartels Source Type: research

Shared Decision-Making Tool for Opioid Prescribing After Ambulatory Orthopedic Surgery in Veterans: A Randomized Controlled Clinical Trial
CONCLUSIONS: The shared-tool group had equivalent or better pain control and were prescribed a lower number of opioid pain pills than the no-tool group. Both groups used nonopioid medications, with no difference in the types of over-the-counter medications used. Shared decision-making strategies could be applied to other outpatient orthopedic surgical settings, and may reduce the amount of opioids prescribed without compromising pain control.TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic II.PMID:35880150 | PMC:PMC9308163 | DOI:10.1016/j.jhsg.2022.05.003 (Source: Hand Surgery)
Source: Hand Surgery - July 26, 2022 Category: Surgery Authors: Rajshri Bolson Andy Lalka Hannah Korrell Sarah E Sibbel Karsten Bartels Source Type: research

The role of computer-assisted cryotherapy in the postoperative treatment after total knee arthroplasty: positive effects on pain and opioid consumption
ConclusionComputer-assisted cryotherapy following TKA can be beneficial during the first postoperative week in terms of pain reduction and diminished opioid consumption. No clear differences in knee function or swelling were seen.Level of evidenceTherapeutic study with level of evidence I. (Source: Knee Surgery, Sports Traumatology, Arthroscopy)
Source: Knee Surgery, Sports Traumatology, Arthroscopy - July 26, 2022 Category: Orthopaedics Source Type: research